JP-listed companies
TOWA PHARMACEUTICAL CO.,LTD.

TOWA PHARMACEUTICAL CO.,LTD.JP:4553

Market cap

¥150.4B

P/E ratio

9.3x

Income statement Balance sheet Cash flow

	Mar 31, 2013	Mar 31, 2014	Mar 31, 2015	Mar 31, 2016	Mar 31, 2017	Mar 31, 2018	Mar 31, 2019	Mar 31, 2020	Mar 31, 2021	Mar 31, 2022	Mar 31, 2023	Mar 31, 2024
Net sales	55,241	61,351	71,470	82,115	84,949	93,430	105,104	110,384	154,900	165,615	208,859	227,934
Cost of sales	27,500	31,121	34,487	40,261	45,902	50,379	56,705	59,738	89,448	95,429	136,145	146,551
Gross profit (loss)	27,741	30,230	36,983	41,854	39,046	43,050	48,399	50,646	65,451	70,185	72,713	81,383
Selling, general and administrative expenses	20,018	22,523	25,877	30,719	32,176	31,407	32,431	34,503	45,527	50,980	67,199	63,735
Operating profit (loss)	7,723	7,706	11,105	11,134	6,869	11,643	15,968	16,143	19,923	19,205	5,514	17,647
Interest income	49	46	110	103	29	58	48	81	23	8	17	97
Interest and dividend income	-	-	-	-	-	-	-	-	-	-	75	92
Dividend income	3	3	5	4	4	4	5	5	6	6	8	9
Foreign exchange gains	77	275	527	714	551	603	958	722	770	795	1,181	1,593
Foreign exchange gains	77	275	527	714	551	603	958	722	770	795	1,181	1,593
Gain on valuation of derivatives	1,151	331	2,999	-	-	-	1,144	3,672	-	2,896	-	5,550
Gain on valuation of derivatives	1,151	331	2,999	-	-	-	1,144	3,672	-	2,896	-	5,550
Subsidy income	322	59	54	538	99	590	466	170	305	310	205	362
Subsidy income	322	59	54	538	99	590	466	170	305	310	205	362
Reversal of allowance for doubtful accounts	58	83	10	-	272	-	315	28	4	2	202	274
Other	162	371	685	625	623	374	296	349	377	528	1,477	498
Non-operating income	2,082	1,308	4,488	1,987	1,307	1,632	3,234	5,031	1,488	4,546	2,889	8,111
Interest expenses	109	122	135	163	164	158	146	131	190	230	635	947
Loss on valuation of derivatives	-	-	-	2,280	502	1,334	-	-	2,388	-	1,850	-
Loss on sale of securities	96	-	-	-	-	-	-	-	-	-	7	-
Other	54	38	21	520	92	65	184	52	155	111	776	335
Loss on valuation of derivatives	-	-	-	2,280	502	1,334	-	-	2,388	-	1,850	-
Non-operating expenses	261	180	156	2,965	760	1,557	337	184	2,734	1,011	3,262	1,282
Other	54	38	21	520	92	65	184	52	155	111	776	335
Non-operating expenses	261	180	156	2,965	760	1,557	337	184	2,734	1,011	3,262	1,282
Ordinary profit (loss)	9,544	8,834	15,437	10,157	7,417	11,717	18,865	20,990	18,677	22,739	5,141	24,477
Gain on sale of non-current assets	5	-	-	1	1	-	2	-	245	123	17	313
Other	-	-	-	-	-	-	-	-	-	-	-	-
Extraordinary income	11	-	-	1	1	-	300	-	245	123	18	313
Extraordinary income	11	-	-	1	1	-	300	-	245	123	18	313
Loss on disposal of non-current assets	129	63	213	238	177	83	41	6	148	27	63	88
Loss on valuation of investment securities	-	-	-	-	-	-	-	225	19	58	20	222
Other	-	-	17	16	3	-	-	-	-	25	470	19
Extraordinary losses	245	132	231	254	180	1,883	279	281	194	616	554	331
Extraordinary losses	245	132	231	254	180	1,883	279	281	194	616	554	331
Profit (loss) before income taxes	9,310	8,702	15,206	9,903	7,237	9,833	18,886	20,709	18,728	22,246	4,605	24,459
Income taxes - current	3,271	2,392	4,371	2,247	1,741	3,411	5,595	6,542	4,971	6,155	3,038	8,818
Income taxes - deferred	-161	317	-283	-28	-79	-73	-185	-336	314	176	-633	-532
Income taxes	3,109	2,710	4,088	2,219	1,661	3,338	5,410	6,206	4,770	6,331	2,404	8,286
Profit (loss)	-	-	11,118	7,684	5,576	6,495	13,475	14,503	13,958	15,914	2,201	16,173
Profit (loss) attributable to owners of parent	-	-	11,118	7,684	5,576	6,495	13,475	14,503	13,958	15,914	2,201	16,173